Distinct functions of wild-type and R273H mutant Δ133p53α differentially regulate glioblastoma aggressiveness and therapy-induced senescence

Sebastien M. Joruiz,Natalia Von Muhlinen,Izumi Horikawa,Mark R. Gilbert,Curtis C. Harris

DOI: https://doi.org/10.1038/s41419-024-06769-5

2024-06-27

Cell Death and Disease

Abstract:Despite being mutated in 92% of TP53 mutant cancers, how mutations on p53 isoforms affect their activities remain largely unknown. Therefore, exploring the effect of mutations on p53 isoforms activities is a critical, albeit unexplored area in the p53 field. In this article, we report for the first time a mutant Δ133p53α-specific pathway which increases IL4I1 and IDO1 expression and activates AHR, a tumor-promoting mechanism. Accordingly, while WT Δ133p53α reduces apoptosis to promote DNA repair, mutant R273H also reduces apoptosis but fails to maintain genomic stability, increasing the risks of accumulation of mutations and tumor's deriving towards a more aggressive phenotype. Furthermore, using 2D and 3D spheroids culture, we show that WT Δ133p53α reduces cell proliferation, EMT, and invasion, while the mutant Δ133p53α R273H enhances all three processes, confirming its oncogenic potential and strongly suggesting a similar in vivo activity. Importantly, the effects on cell growth and invasion are independent of mutant full-length p53α, indicating that these activities are actively carried by mutant Δ133p53α R273H. Furthermore, both WT and mutant Δ133p53α reduce cellular senescence in a senescence inducer-dependent manner (temozolomide or radiation) because they regulate different senescence-associated target genes. Hence, WT Δ133p53α rescues temozolomide-induced but not radiation-induced senescence, while mutant Δ133p53α R273H rescues radiation-induced but not temozolomide-induced senescence. Lastly, we determined that IL4I1, IDO1, and AHR are significantly higher in GBMs compared to low-grade gliomas. Importantly, high expression of all three genes in LGG and IL4I1 in GBM is significantly associated with poorer patients' survival, confirming the clinical relevance of this pathway in glioblastomas. These data show that, compared to WT Δ133p53α, R273H mutation reorientates its activities toward carcinogenesis and activates the oncogenic IL4I1/IDO1/AHR pathway, a potential prognostic marker and therapeutic target in GBM by combining drugs specifically modulating Δ133p53α expression and IDO1/Il4I1/AHR inhibitors.

cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the different functions of wild - type (WT) and mutant - type (R273H) Δ133p53α in glioblastoma (GBM) and their impacts on tumor invasiveness and treatment - induced cellular senescence. Specifically, the research focuses on the following aspects:

1. **The impact of mutations on the activity of p53 isoforms**:
- Although the TP53 gene is mutated in 92% of cancers, how these mutations affect the activity of p53 isoforms remains unknown. Therefore, exploring the impact of mutations on the activity of p53 isoforms is a crucial but under - studied area.

2. **The specific pathway of mutant Δ133p53α**:
- The research has found that mutant Δ133p53α promotes tumor development by increasing the expression of IL4I1 and IDO1 and activating AHR (aryl hydrocarbon receptor). This mechanism is significantly different from the function of wild - type Δ133p53α.

3. **Cell proliferation, EMT and invasiveness**:
- Research shows that wild - type Δ133p53α reduces cell proliferation, epithelial - mesenchymal transition (EMT) and invasiveness, while mutant - type Δ133p53αR273H enhances these processes, indicating its oncogenic potential.

4. **Regulation of cellular senescence**:
- Mutant - type Δ133p53αR273H and wild - type Δ133p53α exhibit different mechanisms in regulating cellular senescence. Wild - type Δ133p53α mainly reduces cellular senescence by inhibiting p21 expression, while mutant - type Δ133p53αR273H achieves this purpose by reducing IGFBP7 expression.

5. **Clinical relevance**:
- The research also found that the expressions of IL4I1, IDO1 and AHR in GBM patients are significantly higher than those in low - grade glioma (LGG) patients, and high expressions of these genes are associated with poorer survival rates, which further confirms the clinical significance of these genes in glioblastoma.

In conclusion, this paper aims to reveal the different functions of wild - type and mutant - type Δ133p53α in glioblastoma, especially how they affect tumor invasiveness and treatment response, as well as the potential clinical application value of these findings.